Contingency management is efficacious and improves outcomes in cocaine patients with pretreatment marijuana use
- PMID: 21440999
- PMCID: PMC3143207
- DOI: 10.1016/j.drugalcdep.2011.03.001
Contingency management is efficacious and improves outcomes in cocaine patients with pretreatment marijuana use
Abstract
Background: Marijuana use is common in patients seeking treatment for cocaine use. Nevertheless, few studies have examined effects of marijuana use on treatment outcomes in general, and even fewer with respect to contingency management (CM) treatment, which has been criticized for potentially increasing non-reinforced drug use.
Methods: Data from three randomized clinical trials of CM versus standard treatment (ST) in cocaine-abusing patients were examined (Petry et al., 2004, 2005a, 2006a; N=393) to assess effects of pretreatment marijuana use on outcomes. Patients were divided into two groups: (1) no self-reported marijuana use (No Pre-M; n=315) and (2) any self-reported marijuana use (Pre-M; n=78) in the 30 days pretreatment.
Results: CM was especially efficacious in enhancing retention in Pre-M patients such that retention nearly doubled among Pre-M patients assigned to CM versus those assigned to ST. In contrast, CM exerted only modest benefits on retention in No Pre-M patients. Pretreatment marijuana use was not related to during-treatment abstinence from cocaine, opioids, and alcohol, or abstinence at a Month 9 follow-up. However, CM treatment and longest duration of abstinence achieved during treatment were significant predictors of Month 9 abstinence. Pre-M patients also evidenced more improvements in drug problems over time when randomized to CM.
Conclusions: CM was especially efficacious in facilitating retention and improving severity of drug-related problems in those who used marijuana in the month before initiating treatment.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.
References
-
- Aharonovich E, Garawi F, Bisaga A, Brooks D, Raby WN, Rubin E, Nunes EV, Levin FR. Concurrent cannabis use during treatment for comorbid ADHD and cocaine dependence: effects on outcome. Am. J. Drug Alcohol Abuse. 2006;32:629–635. - PubMed
-
- Aharonovich E, Lui X, Samet S, Nunes E, Waxman R, Hasin D. Postdischarge cannabis use and its relationship to cocaine, alcohol, and heroin use: a prospective study. Am. J. Psychiatry. 2005;162:1507–1514. - PubMed
-
- Bovasso GB, Alterman AI, Cacciola JS, Cook TG. Predictive validity of the Addiction Severity Index’s composite scores in the assessment of 2-year outcomes in a methadone maintenance population. Psychol. Addict. Behav. 2001;15:171–176. - PubMed
-
- Browne MW, Cudeck R. Alternate ways of assessing model fit. In: Bollen KA, Long JS, editors. Testing Structural Equation Models. Sage; Beverly Hills, CA: 1993. pp. 136–162.
-
- Budney AJ, Higgins ST, Hughes JR, Bickel W. Nicotine and caffeine use in cocaine dependent individuals. J. Subst. Abuse Treat. 1993;5:117–130. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 DA013444/DA/NIDA NIH HHS/United States
- P30-DA023918/DA/NIDA NIH HHS/United States
- T32-AA07290/AA/NIAAA NIH HHS/United States
- R01-DA024667/DA/NIDA NIH HHS/United States
- P50 DA009241/DA/NIDA NIH HHS/United States
- R01 DA024667/DA/NIDA NIH HHS/United States
- R01 DA018883/DA/NIDA NIH HHS/United States
- R01-DA021567/DA/NIDA NIH HHS/United States
- R01-DA022739/DA/NIDA NIH HHS/United States
- P60 AA003510/AA/NIAAA NIH HHS/United States
- R01-DA016855/DA/NIDA NIH HHS/United States
- R01-DA027615/DA/NIDA NIH HHS/United States
- R01-DA13444/DA/NIDA NIH HHS/United States
- R01 DA027615/DA/NIDA NIH HHS/United States
- R01-DA018883/DA/NIDA NIH HHS/United States
- R21-DA021836/DA/NIDA NIH HHS/United States
- R01 DA014618/DA/NIDA NIH HHS/United States
- R01 DA022739/DA/NIDA NIH HHS/United States
- M01-RR06192/RR/NCRR NIH HHS/United States
- R01 DA016855/DA/NIDA NIH HHS/United States
- R21 DA021836/DA/NIDA NIH HHS/United States
- R01-DA14618/DA/NIDA NIH HHS/United States
- P60-AA03510/AA/NIAAA NIH HHS/United States
- P30 DA023918/DA/NIDA NIH HHS/United States
- P50-DA09241/DA/NIDA NIH HHS/United States
